Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS
Determine if the addition of filibuvir to a standard of care (SOC) regimen of pegylated interferon alpha 2a (Pegasys) and ribavirin (Copegus) significantly increases the proportion of subjects who ach...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 5 ans
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
- To determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with venous thromboembolism (VTE), and with or without cancer, using anti-Xa ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Consumer Healthcare, Pfizer Health AB
MAJ Il y a 5 ans
AN EVALUATOR-BLINDED, OPEN, RANDOMIZED, PARALLEL CONTROLLED STUDY ON NICORETTE® FRESHMINT GUM VS NICORETTE® MICROTAB IN HEALTHY SMOKERS MOTIVATED TO QUIT SMOKING AND WITH VISIBLE STAINING OF TEETH
To assess, by the MacPherson Modification of the Lobene Stain Index (9, 10), the amount of extrinsic tooth stain reduction from baseline while quitting smoking using Nicorette® Freshmint, and Nicorett...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Study is fully funded by Pfizer Inc. (USA)
MAJ Il y a 5 ans
A randomized double blind placebo controlled study to evaluate the modulation of cognitive functions in Parkinson's subjects by sildenafil
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 5 ans
[S,S]-REBOXETINE ADD-ON TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN) CONCOMITANTLY TREATED WITH PREGABALIN
To compare the efficacy of adjunctive treatment of pregabalin with [S,S]-RBX against pregabalin monotherapy in patients with PHN
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES
• To evaluate the escalating single- and multiple-dose safety and tolerability of pregabalin, in comparison to placebo, in pediatric patients 1 month through 16 years of age with partial onset seizure...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Support from Sanofi-Aventis, Roche Pharma and Pfizer
MAJ Il y a 5 ans
A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy
Not provided at time of registration
Pays
France
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
The primary objective of this Protocol is to assess the efficacy of PF-04447943, relative to placebo, on a performance-based measure of cognition in subjects with mild to moderate AD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A multi-center, multinational, randomized, double-blind, placebo-controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 Modified Release on exercise capacity in subjects with pulmonary hypertension associated with chronic obstructive pulmonary disease
To evaluate the effects of UK-369,003MR on exercise capacity as measured by change frombaseline in distance walked during the 6 Minute Walk Test (6MWT) after 12 weeks of treatment in subjects with PH ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer (Netherlands)
MAJ Il y a 5 ans
Effects of growth hormone treatment after final height in Prader-Willi Syndrome
Not provided at time of registration
Pays
Netherlands
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant